Johnson & Johnson (JNJ, Financial) recently announced that it will cease the development of a combination therapy using nipocalimab with an anti-tumor necrosis factor alpha for treating rheumatoid arthritis (RA). This decision follows results from the Phase 2a DAISY proof-of-concept study, which aimed to test the potential effectiveness of this combination in patients with refractory RA. After 12 weeks, the study did not show significant added benefits over the anti-TNFalpha therapy alone. However, no new safety issues were reported during the trial.
Despite this setback, Johnson & Johnson remains optimistic about the future of nipocalimab. The company continues its broader clinical development program for nipocalimab, focusing on its potential in treating various conditions, including Rheumatic, Rare Autoantibody, and Maternal Fetal diseases. Johnson & Johnson is confident in the product's market potential, projecting it could exceed $5 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.